Leukotrienes: Bridging the Inflammatory Gap in Asthma and Inflammatory Bowel Diseases ( IBD )
Comprehensive Physiology · 2025-06 · 15 (3)
DOI: 10.1002/cph4.70022 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Comprehensive Physiology, online erschienen am 26.06.2025. Verfasst von Emma Elizabeth Sabu Kattuman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Pharmacology, The University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Asthma, Leukotrienes. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 204 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NHLBI NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Leukotrienes are potent inflammatory lipid mediators produced primarily by immune cells. Inflammation, being the center stone of two major disease conditions, namely, asthma and inflammatory bowel disease (IBD), has led researchers to study the role of leukotrienes (LTs) in both these disease settings extensively. Several studies indicate a crucial role for LTs in the development and progression of IBD, whereas LTs, especially cysteinyl leukotrienes (cys‐LTs), have been identified as the major contributors to asthma initiation and progression for over three decades. Additionally, the lungs and the gut share several common characteristics, including their exposure to the external environment, similar microbiome composition, and inflammatory responses. These similarities suggest a bidirectional relationship, supported by the increased risk of IBD in asthma patients and vice versa. However, the specific role of LTs in this lung–gut connection remains unclear. This review will examine how several common factors, such as physiology, microbiome, environment, and inflammatory mediators, especially LTs, modulate this crosstalk. The review also highlights in detail how altered leukotriene biosynthesis and signaling contribute to the pathogenesis of both asthma and IBD. Furthermore, we will consider the therapeutic implications of targeting leukotriene pathways for patients with concurrent asthma and IBD in the hope of developing more efficient treatment outcomes for these interconnected conditions. Finally, this review will very briefly explore the involvement of neuronal connections in mediating the lung–gut crosstalk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology and Pharmacology, The University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
ORCID-Profile: Emma Elizabeth Sabu Kattuman, Lakshminarayan Reddy Teegala, Somayeh Darzi, Charles K Thodeti, Sailaja Paruchuri
Förderung
- NIH HHS
- NHLBI NIH HHS
- NIAID NIH HHS
- American Heart Association
- National Institutes of Health
Zitieren
APA
Sabu Kattuman, E. E., Teegala, L. R., Darzi, S., Thodeti, C. K., & Paruchuri, S. (2025). Leukotrienes: Bridging the Inflammatory Gap in Asthma and Inflammatory Bowel Diseases ( IBD ). Comprehensive Physiology, 15(3). https://doi.org/10.1002/cph4.70022
Vancouver
Sabu Kattuman EE, Teegala LR, Darzi S, Thodeti CK, Paruchuri S. Leukotrienes: Bridging the Inflammatory Gap in Asthma and Inflammatory Bowel Diseases ( IBD ). Comprehensive Physiology. 2025;15(3). doi:10.1002/cph4.70022
BibTeX
@article{SabuKattuman2025,
author = {Sabu Kattuman, Emma Elizabeth and Teegala, Lakshminarayan Reddy and Darzi, Somayeh and Thodeti, Charles K and Paruchuri, Sailaja},
title = {Leukotrienes: Bridging the Inflammatory Gap in Asthma and Inflammatory Bowel Diseases ( IBD )},
journal = {Comprehensive Physiology},
year = {2025},
volume = {15},
number = {3},
doi = {10.1002/cph4.70022}
}
EUVIMED